HDAC Inhibitor, CG-745, Enhances the Anti-Cancer Effect of Anti-Pd-1 Immune Checkpoint Inhibitor by Modulation of the Immune Microenvironment

Journal of Cancer - Australia
doi 10.7150/jca.44622
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Ivyspring International Publisher

Related search

Systemic Immunotherapy of Superficial Mouse Bladder Cancer With Avelumab (MSB0010718C), an Anti-Pd-L1 Immune Checkpoint Inhibitor

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2015English

Lack of Conventional Acinar Cells in Parotid Salivary Gland of Patient Taking an Anti-Pd-L1 Immune Checkpoint Inhibitor

Frontiers in Oncology
Cancer ResearchOncology
2020English

Pd-1 Immune Checkpoint Blockade Improves Anti-Cd20 Based Immunotherapy in Follicular Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Immune Checkpoint Inhibitor-Induced Fanconi Syndrome

Cureus
2020English

Immune Checkpoint Inhibitor Nephrotoxicity: Update 2020

Kidney360
2020English

Robust Antitumor Effects of Combined Anti-Cd4-Depleting Antibody and Anti-Pd-1/Pd-L1 Immune Checkpoint Antibody Treatment in Mice

Cancer immunology research
Cancer ResearchImmunology
2015English

The Safety and Tolerability of Combined Immune Checkpoint Inhibitors (Anti-Pd-1/Pd-L1 Plus Anti-Ctla-4): A Systematic Review and Meta-Analysis

BMC Cancer
Cancer ResearchOncologyGenetics
2019English

Immune-Checkpoint Inhibitor Treatment of Non-Small Cell Lung Cancer Patients

Jurnal Respirasi
2020English

Development of PARP and Immune-Checkpoint Inhibitor Combinations

Cancer Research
Cancer ResearchOncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy